An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®
Jennifer S. Steger,Indira Durai,Annamalai Odayappan,Ramalakshmi Raman,Talla Sruthi,Allisa J. Song,George Puthuran,Rengaraj Venkatesh,Elizabeth Colantuoni,Alan L. Robin
DOI: https://doi.org/10.1016/j.ophtha.2024.03.012
IF: 14.277
2024-03-16
Ophthalmology
Abstract:Objective or Purpose Examine if 12.5 μL timolol maleate 0.5% microdrops dispensed with the Nanodropper® Adaptor provide non-inferior intraocular pressure (IOP) reduction compared to conventional, 28 μL drops in open-angle glaucoma (OAG) and ocular hypertension (OHT) patients. Design Prospective, non-inferiority, parallel, multicenter, single-masked, active-controlled, randomized trial. Subjects, Participants, and/or Controls Treatment-naïve subjects that were recently diagnosed with OAG/OHT at the Aravind Eye Care System. Methods, Intervention, or Testing Both eyes of subjects received either one commercially available drop or one microdrop of timolol maleate 0.5%. We measured IOP, resting heart rate (HR), and blood pressure (BP) at baseline and 1, 2, 5, and 8 hours after timolol administration. Main Outcome Measures IOP was the primary outcome measure. Secondary outcomes were resting HR, systolic BP (sBP), and diastolic BP (dBP). Results Adaptor-mediated microdrops and conventional drops of timolol significantly decreased IOP compared to baseline at all timepoints. Non-inferiority was established at three of four timepoints. HR decreases with Nanodropper were ∼3 bpm less than with conventional drops. Conclusions Timolol microdrops appear to be as effective in ocular hypotensive action as conventional drops with a slightly lesser effect on resting HR and BP.
ophthalmology